Drug Discovery Using Chemoproteomics Platform
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
403
NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 12, 2024
Completion: Apr 30, 2028
Loading map...